<DOC>
	<DOC>NCT01337089</DOC>
	<brief_summary>This is a six-month extension study to evaluate the safety of long-term Sativex速 therapy when used as an adjunctive measure in patients with advanced cancer. The study provides continued availability of Sativex速 to patients who completed the preceding Phase 3 study.</brief_summary>
	<brief_title>Long Term Safety of Sativex速 Oromucosal Spray (Sativex速; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain</brief_title>
	<detailed_description />
	<criteria>Patient has completed the parent study within the last seven days Willing and able to give written informed consent Willing and able to comply with all study requirements The patient is currently using cannabis or cannabinoid based medications, other than the parent study IMP, and is unwilling to abstain for the duration of the study Any history or immediate family history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition Any known or suspected history of a substance abuse/dependence disorder (including opiate abuse/dependence prior to the diagnosis of cancer) Has poorly controlled epilepsy or recurrent seizures (i.e. one or more seizure during the last year) Has experienced myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or has a cardiac disorder that, in the opinion of the investigator would put the patient at risk of a clinically significant arrhythmia or myocardial infarction Has significantly impaired renal function Has significantly impaired hepatic function Female patients of childbearing potential and male patients whose partner is of childbearing potential, unless willing to ensure that they or their partner use effective contraception, for example, oral contraception, double barrier, intrauterine device, during the study and for three months thereafter (however, a male condom should not be used in conjunction with a female condom as this may not prove effective)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>cancer pain</keyword>
	<keyword>opioid therapy</keyword>
	<keyword>inadequate analgesia</keyword>
	<keyword>optimized chronic opioid therapy</keyword>
</DOC>